creat bluematrix
zntl zero leader initi buy rate pt
messag initi coverag zntl buy rate pt zntl focus discov develop small
molecul therapeut target fundament pathway cancer use medicin chemistri platform zntl submit ind
five year sinc incept pipelin product candid initi focus clinic valid oncolog target larg
patient popul main near-term valu driver zntl potenti best-in-class oral select estrogen receptor degrad
serd current phase i/ii clinic trial metastat breast cancer updat clinic data guid
product candid includ inhibitor current phase i/ii clinic trial treatment advanc solid tumor zn-
select inhibitor initi develop treatment hematolog malign irrevers
inhibitor mutant egfr current phase i/ii clinic trial treatment advanc non-smal cell lung cancer nsclc
valu zntl per share support predominantli probability-adjust estim rest pipelin
repres potenti upsid current assumpt
rate zntl buy price target clinical-stag biophmarceut
compani focus discov develop small molecul therapeut target fundament biolog pathway cancer
leverag experi capabl cancer biolog medicin chemistri zntl built product engin result
discoveri new chemic entiti nce uniqu properti pharmacokinet could potenti translat differenti
product candid product engin highli product result ind submiss year sinc incept
ind take less three year discoveri current pipelin candid includ inhibitor target well-valid oncogen
pathway estrogen receptor egfr well emerg new target potenti address unmet medic need
 base-cas valuat consist deriv probability-adjust estim oral
serd pos-adjust estim inhibitor egfr inhibitor inhibitor
well cash expect year upsid scenario show compel clinic product profil ye
believ zntl could valu wherea downsid scenario zntl could worth share ye
high potenti zntl lead product candid emerg best-in-class oral serd target estrogen
receptor er valid target breast cancer therapi signific room improv current approv agent
opinion well posit potenti becom best-in-class oral serd product candid within emerg class
agent given select pk/pd profil high plasma exposur level higher exposur breast cancer patient
compar fulvestr preval breast cancer subtyp repres signific target market
fulvestr faslodex azn current approv serd global sale indic treatment
postmenopaus advanc breast cancer patient previous treat endocrin therapi line well
diseas progress follow endocrin therapi later line either monotherapi combin
inhibitor despit superior efficaci vs wide use aromatas inhibitor phase falcon studi good safeti profil deliveri
via pain hc provider-administ intramuscular inject key factor limit full potenti base interview
physician special breast cancer treatment believ success develop oral serd could significantli expand
current serd market opportun exist improv upon efficaci fulvestr updat result on-going phase
dose-escal studi well initi result phase window opportun studi could provid
insight clinic profil plan phase ii studi either monotherapi combin
inhibitor ibranc follow treatment one prior endocrin therapi could posit competit rel approv
page analyst certif import disclosur
agent base novn-ch trial result current assum success probabl
forecast un-adjust us peak sale oppti metastat breast cancer commerci launch
base case scenario
pipelin addit agent address clinic valid target offer multipl shot goal upsid option
oral inhibitor product candid current undergo phase clinic trial patient advanc solid
tumor follow plan combin studi chemotherapi parp inhibitor key compon dna damag
respons ddr pathway express high level variou cancer type includ breast cancer leukemia melanoma
mani cancer treat dna-damag agent therefor target inhibit compromis
dna repair checkpoint present opportun potenti therapi
azn inhibitor advanc phase ii clinic trial combin dna-damag therapi variou cancer
type demonstr clinic activ optimum dose schedul either alon combin identif patient
specif biomark profil benefit well phase plan establish given drug narrow
therapeut window design significantli select potent given favor absorpt distribut metabol
excret adm pk characterist could potenti result wider therapeut window and/or dose flexibl
initi result on-going phase monotherapi dose-escal studi guid initi chemotherapi
combin dose-escal trial current assum success probabl forecast bn unadjust us peak
sale oppti metastat solid cancer commerci launch base case scenario
zntl coval mutant-egfr inhibitor design avoid wild-typ egfr bind small-molecul kinas
inhibitor target mutant-egfr repres well-valid class agent treatment non-smal cell lung cancer
gener bn sale acquir egfr mutat repres well understood mechan resist first
gener iressa azn tarceva second gener gilotrif boehring ingelheim vizimpro tagrisso azn
third gener egfr inhibitor address primari exon egfr alter also secondari mutat
clinic commerci success bn sale design potent inhibit mutant egfr
includ resist mutat less activ toward wild-typ egfr lack known metabolit tagrisso
thought respons hallmark side effect egfr inhibitor skin rash current
evalu phase i/ii dose escal studi patient advanc nsclc activ egfr mutat progress
follow therapi egfr tyrosin kinas inhibitor zntl plan present updat result studi current
assum success probabl forecast unadjust us peak sale oppti egfr nsclc
commerci launch base case scenario
potent inhibitor target zntl design optim potenc select pk rel
venclexta sale goal reduc activ toward bcl-xl thought result thrombocytopenia
low platelet side-effect addit preclin experi show bind high affin certain mutant
thought caus resist venclexta treatment cll model zntl submit ind fda march plan
initi phase clinic trial patient aml b-cell lymphoma long-term develop plan
includ potenti evalu combin serd patent breast cancer base support clinic
data emerg form investigator-initi trial combin venclexta tamoxifen-bas endocrin therapi
upcom potenti stock catalyst pipelin event follow interim result monotherapi dose escal
cohort phase i/ii studi zntl expect provid updat result could provid visibl pk/pd
properti safeti profil especi higher dose anoth key potenti catalyst initi result phase window
opportun studi guid posit result demonstr exampl signific degrad er reduct
progesteron receptor pr could substanti derisk develop current evalu phase
dose escal studi initi result expect posit could potenti valid effect therapeut
target provid insight clinic strategi lastli updat result phase dose escal guid
page analyst certif import disclosur
initi coverag zentali
page analyst certif import disclosur
tabl content
oral serd breast cancer
inhibitor solid tumor
iv egfr inhibitor nsclc
inhibitor cll/aml
page analyst certif import disclosur
page analyst certif import disclosur
rate zntl buy zntl focus discov
pathway cancer use medicin chemistri platform zntl
submit ind five year sinc incept pipelin product
candid initi focus clinic valid oncolog target
larg patient popul main near-term valu driver zn-
degrad serd current phase i/ii clinic trial
metastat breast cancer updat clinic data guid
valu zntl per share support predominantli
probability-adjust estim rest pipelin
repres potenti upsid current assumpt
probabl success po breast
competit posit vs oral serd
program develop
market potenti breast cancer
clinic profil competit posit zntl
inhibitor egfr inhibitor
updat result oral serd phase
initi monotherapi combin phase
initi result phase window opportun
initi result inhibitor phase
initi result egfr inhibitor phase
dose escal cohort egfr nsclc
initi phase trial inhibitor
chart slide overal market perform
page analyst certif import disclosur
zentali zntl emerg biopharmaceut compani focus discov develop small molecul
therapeut target fundament biolog pathway cancer compani develop highli effici drug discoveri platform identifi new
chemic entiti specif properti could potenti result differenti product profil zntl submit ind five year sinc
incept pipelin product candid initi focus valid oncolog target larg patient popul
lead product candid oral select estrogen receptor degrad serd current phase i/ii clinic trial metastat
breast cancer updat clinic data guid product candid includ inhibitor current phase i/ii clinic trial
treatment advanc solid tumor select inhibitor initi develop treatment hematolog malign
irrevers inhibitor mutant egfr current phase i/ii clinic trial treatment advanc non-smal cell lung cancer nsclc
ph window opportun
page analyst certif import disclosur
candid larg valid market
could potenti best-in-class oral serd
multipl potenti catalyst though end
clinic phase data serd program still earli
differenti profil may discern
clinic trial phase ii data avail
zntl pipelin agent target highli complet
still limit line sight early-stag asset wee
growth diversifi pipelin ind submiss
year sinc incept ind take less three
year discoveri current pipelin candid address well-
valid oncogen pathway larg market opportun
high potenti zntl lead product candid
emerg best-in-class oral serd target
estrogen receptor er valid target breast cancer
therapi signific room improv current
approv agent opinion well posit
potenti becom best-in-class oral serd product
candid within emerg class agent given
select pk/pd profil high plasma exposur level
higher exposur breast cancer patient compar
pipelin addit agent address clinic
valid target offer multipl shot goal upsid
option addit zntl clinic stage pipelin
candid includ inhibitor target egfr
molecul design potenti address
drawback competitor agent clinic updat guid
page analyst certif import disclosur
po breast cancer
po solid tumor
po lung cancer
po aml/cll
per dcf
assumpt compar develop stage
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
posit clinic data updat
phase dose-escalation/expans trial well
support data biomark window studi
initi phase ii trial
market share
disappoint data readout phase
window studi increas competit
concern oral serd space
market share
page analyst certif import disclosur
zntl platform focus small molecul drug discoveri target
fundament pathway cancer
zntl focus discov develop small molecul therapeut target fundament
biolog pathway cancer
leverag experi capabl cancer biolog medicin chemistri zntl
built product engin focus discoveri new chemic entiti nce uniqu
properti pharmacokinet could potenti translat differenti product
product engin highli product result ind submiss year
sinc incept ind take less three year discoveri
current pipelin candid includ inhibitor target well-valid oncogen pathway
estrogen receptor egfr well emerg new target potenti
page analyst certif import disclosur
zntl pipelin consist select inhibitor variou valid
target potenti larg target market
page analyst certif import disclosur
presid chief execut offic bod
former partner aisl capit
current cso bod
prior role perseus-soro biopharmaceut fund
board director immusoft corpor eyenovia
inc small-molecul drug discoveri develop
prior role medicin chemistri depart
former cfo psioxu
former chief develop offic curevac ag
former cfo head busi develop r-
director credit-focus
prior role goldman sach bain compani
former senior vice presid head global clinic
develop oncolog busi group eisai
former vice presid head global develop
specialti medicine/oncolog bayer healthcar
page analyst certif import disclosur
guggenheim balanc sheet forecast
page analyst certif import disclosur
michael schmidt incom statement royalty- total cogs- royalti recurium- total cost oper incom interest expense- net incom incom net loss attribut non-controlling net incom basic ep per dilut ep per share outstand outstand cf short-term debt- oral serd breast cancer
page analyst certif import disclosur
takeaway zntl lead pipelin asset key valu driver
oral serd target estrogen receptor er valid target breast cancer signific
room improv current approv agent believ well posit potenti becom
best-in-class oral serd product candid within emerg class agent given select
pk/pd profil high plasma exposur level higher exposur breast cancer patient compar
preval breast cancer subtyp repres signific target market zn-
fulvestr faslodex azn current approv serd global sale indic
treatment postmenopaus advanc breast cancer patient previous treat
endocrin therapi line well diseas progress follow endocrin therapi
later line either monotherapi combin inhibitor
despit superior efficaci vs aromatas inhibitor signific improv demonstr
ph falcon studi good safeti profil deliveri via hc provider-administ intramuscular inject
key factor limit full potenti base interview breast cancer physician believ
success develop oral serd could potenti significantli expand current serd market
opportun exist potenti improv upon efficaci fulvestr
updat result on-going phase dose-escal studi well initi result phase
window opportun studi could provid insight clinic profil
current assum success probabl forecast bn unadjust us peak sale opportun
metastat breast cancer commerci launch peak market
share base case scenario
page analyst certif import disclosur
preval breast cancer subtyp
breast cancer epidemiolog statist
breast cancer commonli occur
cancer women second common
estim new case breast cancer
us new cancer case
includ death cancer death
averag surviv rate
vari diseas stage subgroup
breast cancer categor base two
factor receptor hr hormon receptor
includ estrogen receptor er progesteron
receptor pr treatment vari differ
page analyst certif import disclosur
endocrin therapi inhibit cornerston
overview breast cancer treatment paradigm
chemo ac doxorubicin/cyclophosphamid follow paclitaxel
endocrin therapi et aromatas inhibitor ai serm tamoxifen
guggenheim secur llc nccn guidelin breast cancer link physician choic nab-paclitaxel paclitaxel gemcitabine/carboplatin
page analyst certif import disclosur
estrogen receptor er valid major therapeut target
therapeut target breast cancer
letrozol anastrozol
aromatas inhibitor ai inhibit aromatas synthesi estrogen receptor er ligand
estradiol caus bone complic given role estradiol signal bone format
select estrogen receptor modul serm partial inhibit er dna transcript
activ keep er dimer function configur er retain access chromatin
activ attenu er dimer reduc er access chromatin
page analyst certif import disclosur
overview treatment paradigm breast cancer
page analyst certif import disclosur
endocrin therapi well-establish class drug breast cancer
page analyst certif import disclosur
faslodex fulvestr azn approv serd
efficaci faslodex mg breast cancer
et
et
accord phase falcon studi fulvestr vs anastrozol fulvestr
superior efficaci anastrozol breast cancer
guggenheim secur llc analysi imag zntl fill
faslodex rel well toler phase
confirm studi common clinic
signific advers reaction occur
patient receiv faslodex mg
headach back pain fatigu pain extrem hot
musculoskelet pain cough dyspnea
alp occur faslodex patient
dose-depend
page analyst certif import disclosur
potenti limit administr pharmacodynam
ml gener cite adult maximum volum
singl im inject lower maximum propos adult patient
less-develop small muscl mass
faslodex achiev bn ww sale patent expir
limit mg faslodex degrad
er base result two separ clinic studi
guggenheim secur llc analysi imag zntl fill beyea et al appl nur link kuter et al breast cancer treat
page analyst certif import disclosur
preclin studi highlight pk/pd properti potenti
combin inhibitor
anti-tumor activ breast cancer xenograft model
anti-tumor activ pdx model
show dose-depend anti-tumor activ singl agent
increas activ observ combin palbociclib
increas anti-tumor activ observ combin either
palbciclib abemaciclib pdx model
pk comparison mous model
pd comparison cell model
better pharmacokinet pk indic drug exposur auc oral avail
compar oral serd mous model
potenc demonstr anti-
prolif er-degrad activ cell
guggenheim secur llc imag zntl fill
 fraction oral administ drug reach system circul
page analyst certif import disclosur
current two phase clinic studi includ combin
ibranc
prior chemotherapi
data report
window opportun
prior endocrin
prior endocrin
therapi prior chemotherapi
one dose level
chemotherapi
primari object
prior endocrin
confirm safeti pk
qd day
resect core needl tumor
analysi tumor biomark
page analyst certif import disclosur
preclin profil
clinic benefit ph dose escal indic swim plot
februari four dose
evalu mg qd
patient dose escal part
phase heavili pre-treat
prior chemotherapi
patient met definit
pr cr
patient dose
two patient
dose low dose mg
show sd close month
safeti overal well
patient includ
nausea patient anemia
vomit arthralgia back pain
cough patient
advers event
patient teae grade
singl case
pain pain extrem none
relat diarrhea
observ two patient grade
mg/day deem relat
treatment grade
mg/day deem relat
number treatment reflect advanc metastat set neo/adjuv also reflect combin target therapi
tbd determin
guggenheim secur llc imag zntl fill
page analyst certif import disclosur
compar oral serd show significantli
higher exposur level phase consist preclin profil
comparison clinic pk profil oral serd develop
median cv cmax auc steadi state
median rang tmax steadi state
limit maximum volum intramuscular inject
page analyst certif import disclosur
overview efficaci data competitor oral serd develop
difficult compar across trial
monotherapi dose escal data sabc
ph window
mg mg mg evalu
support ultim dose select
data report hamilton et al clin cancer
ph window
ph window
data report sabc abstract
fail superior fulvestr
data report abstract
data report sabc abstract
monotherapi dose escal data report
palbociclib combo trial initi
page analyst certif import disclosur
pk/pd like key limit factor base window
opportun studi result support zntl hypothesi view
ph window opportun studi compar
effect fulvestr estrogen receptor er
progesteron receptor pr level treatment-na
patient primari breast cancer await cur intent
pk/pd like key limit factor mg
significantli lower exposur mg
fulvestr er degrad potenc similar
in-vitro model
chang express level er pr drug treatment
comparison exposur auc breast cancer patient
comparison potenc er express chang
treatment preclin model
pharmacodynam analysi measur er degrad pr
express level chang treatment fulvestr
mean reduct er h-score
group fulvestr group
mgbid superior fulvestr mg
guggenheim secur llc analysi imag azn compani present
page analyst certif import disclosur
second line breast cancer low-hang fruit initi
data summari combo studi breast cancer
mo
et
sledg et al journal clin
pool
physician choic
chemo et
pivot et al annal oncol
guggenheim secur llc analysi physician choic includ vinorelbin gemcitabin capecitabin taxan anthracyclin chemo hormon therapi
page analyst certif import disclosur
first-lin breast cancer key opportun fulvestr
superior aromatas inhibitor ai still prefer accord doc
data summari combo studi breast cancer
mo
mo
mo
mo
mo
page analyst certif import disclosur
adjuv treatment breast cancer patient potenti
upsid opportun oral serd longer term
summari on-going phase studi breast cancer
elacestr vs standard care anastrozol
page analyst certif import disclosur
kol feedback indic signific potenti oral serd
summari physician interview
front-lin metastat breast cancer inhibitor therapi combin endocrin therapi et mainstay
therapi accord kol spoke
oral aromatas inhibitor ai anastrozol prefer choic et ai-nav metastat patient fulvestr serd
use patient progress ai use adjuv set within year despit effect fulvestr appear
reserv later line patient mani case small minor patient receiv singl agent et
among inhibitor pfe ibranc prefer first choic agent novn kisqali lli verzenio given high physician
comfort drug lack cardiolog monitor lower diarrhea rate verzenio ekg monitor hurdl
adopt kisqali
second-lin set standard care typic includ fulvestr without inhibitor physician sometim rotat
anoth even though there data support fulvestr use limit also requir im inject administr
still straightforward typic requir skill hc provid administ larg needl buttock close proxim
base mechan action serd select estrogen receptor degrad also potenti advantag ai term safeti
ai block synthesi estradiol essenti bone format therefor caus joint pain bone complic serd
hand protect bone loss
kol spoke see oral serd potenti replac fulvestr current market base case uptak line set
would requir demonstr month benefit ai-bas combin kol believ oral serd could potenti
penetr adjuv set even replac ai longer term
one kol believ pharmacokinet exposur import differenti factor oral serd relat clinic activ
page analyst certif import disclosur
current forecast bn us bn global unadjust peak
sale potenti assum po
annual us incid breast cancer
develop metastat diseas
oral serd use breast cancer
patient resist ai therapi elig
patient thearpi
captur peak market share oral serd year post
launch probabl success po
net price launch annual increas
page analyst certif import disclosur
breast cancer cancer pt diagnos stage i- metastat diagnos stage unresect iv number metastat er /or pr prior et patient receiv oral patient receiv patient receiv prior et patient receiv oral patient receiv patient receiv therapi pt progress pt nave oral patient receiv oral patient receiv patient receiv therapi inhibitor solid tumor
page analyst certif import disclosur
takeaway zntl inhibitor address synthet
lethal dna damag respons pathway
oral inhibitor product candid undergo phase clinic trial patient
advanc solid tumor follow plan combin studi chemotherapi parp inhibitor
key compon dna damag respons ddr pathway express high level
variou cancer type includ breast cancer leukemia melanoma mani cancer treat
dna-damag agent therefor target inhibit compromis dna repair
checkpoint present opportun potenti therapi
azn advanc phase ii clinic trial combin dna-damag therapi variou
cancer type demonstr clinic activ optimum dose schedul either alon combin
identif patient specif biomark profil benefit well phase plan
establish given drug narrow therapeut window
design significantli select potent in-vivo given favor absorpt distribut
metabol excret adm pk characterist could potenti result wider therapeut
window and/or dose flexibl
initi result on-going phase monotherapi dose-escal studi guid initi
chemotherapi combin dese-escal trial
current assum success probabl forecast us peak sale opportun
metastat solid cancer commerci launch base case scenario
page analyst certif import disclosur
kinas play critic role resist dna damag
mechan target cancer therapi
kinas play crucial role
suggest
evid cell cycl checkpoint arrest
dna repair mitot entri
normal cell repair damag dna
defici checkpoint
depend function checkpoint
dna repair
express high level
cancer leukemia melanoma adult
pediatr brain tumor
therefor target inhibit
compromis checkpoint
present opportun potenti dna-
azn knowledg
kinas inhibitor current
page analyst certif import disclosur
design highli select optim pk
select kinas screen panel
pk data comparison anim model
show high drug exposur anim model higher level
accumul tumor could potenti increas therapeut
window lead higher efficacy/safeti profil
select profil
character broad kinas panel
consist mammalian serine/threonin
tyrosin depict respect kinas
dendogram
observ higher select rel
depict overal fewer kinas
affect dendogram
guggenheim secur llc imag zntl fill
page analyst certif import disclosur
